-
Folke et al from Copenhagen, Denmark, studied the consequences of automatic external defibrillator (AED) placement in a large metropolitan area.
-
-
The ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) series of randomized, controlled trials has assessed the role of atorvastatin loading prior to percutaneous coronary intervention (PCI) in both stable and unstable coronary syndromes.
-
Dual antiplatelet therapy with aspirin and clopidogrel has become the standard of care for patients suffering an acute coronary syndrome (ACS). However, there remains a significant incidence of recurrent ACS and mortality even in patients treated with dual antiplatelet therapy.
-
Do patients with diabetes share in the reduction of cardiovascular (CV) risk factors as much as non-diabetics?
-
WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
Based upon an increased incidence of heart failure with alpha 1-adrenergic antagonists treatment of hypertension, there has been concern about using alpha blockers for benign prostatic hypertrophy (BPH) in patients with heart failure, yet these drugs are highly efficacious for this common condition.
-
Pulmonary arterial hypertension (PAH) is a dreaded multifactorial disease that is usually fatal. PAH can be a result of a number of conditions, including chronic thromboembolic hypertension, HIV, and congenital cardiac lessons, such as a large ASD with pulmonary shunting resulting in decreased nitric oxide (NO) expression.
-
Functional mitral regurgitation (FMR), occurring in heart failure, portends an adverse prognosis.
-
This report from the Framingham heart study looks at the prognostic significance of PR interval prolongation in ambulatory, relatively healthy individuals.
